Date: 2017-09-04
Type of information: Research agreement
Compound: ROR-gamma inverse agonists
Company: Abbvie (USA - IL) Inventiva (France)
Therapeutic area:
Type agreement: research - development
Action mechanism: ROR-gamma inverse agonist
Disease:
Details:
- • On September 4, 2017, Inventiva announced the extension of an agreement with Abbvie to continue discovery and development efforts for orally available ROR-gamma inverse agonists. In addition, to the ongoing work in preclinical discovery and development the company announced that ABBV- 553, AbbVie’s current ROR-gamma inverse agonist lead compound, will cease development following a Phase 1 study.
Financial terms:
- Under the terms of the agreement, Inventiva will receive an undisclosed research payment. Additionally, Inventiva will receive milestone payments when a new candidate is identified. Inventiva will also be eligible for development and sales milestones as well as royalties on sales.
Latest news:
Is general: Yes
